Glenmark Partners With Menarini On Ryaltris
Licensing Deal For Nasal Spray Covers 33 European Countries
Glenmark has struck a marketing deal with Menarini to commercialize the Indian firm’s Ryaltris nasal spray in 33 countries across Europe. The agreement adds to a network of licenses already in place across the world.
You may also be interested in...
Glenmark is celebrating the approval of its Ryaltris nasal spray in 13 European countries, with the Indian company and partner Menarini set to begin rolling out the allergic rhinitis combination product.
Glenmark has struck the latest in a series of commercialization deals for its Ryaltris nasal spray in the form of a ten-year alliance with Bausch Health for the Canadian market.
Having divested a basket of allergy treatments in Russia and the CIS to Dr Reddy’s last year, Glenmark is gearing up to launch its novel Ryaltris nasal spray in a major Eastern Europe market.